Inborn Errors of Metabolism in Pediatric Epilepsy

Overview

Journal J Pediatr Pharmacol Ther

Specialty Pediatrics

Date 2019 Oct 11

PMID 31598103

Citations 1

Authors

Anna S Cosnahan

Christopher T Campbell

Affiliations

Soon will be listed here.

Abstract

Patients with refractory epilepsy from inborn errors of metabolism typically present as neonates. Direct supplementation with the deficient vitamin or cofactor is recommended, and case series report both efficacy and safety data of these agents. Some conditions may also occur together, necessitating multiple treatments. Despite effective and early treatment, patients are at heightened risk for neurological sequela. The literature on seizures related to metabolic deficiencies for pediatric patients is limited but has some guidance on appropriate dosing and monitoring for agents to target specific deficiencies, which may help with narrowing antiepileptic therapies, reducing side effects, and improving neurodevelopmental outcomes and quality of life. The focus of this review is to discuss the pharmacotherapy, including the most updated published efficacy and safety data, involved in treating refractory epilepsy as a result of metabolic errors.

Citing Articles

Metabolic Epilepsy.

Reddy C, Saini A Indian J Pediatr. 2020; 88(10):1025-1032.

PMID: 33063276 DOI: 10.1007/s12098-020-03510-w.

References

Baynes K, Farias S, Gospe Jr S . Pyridoxine-dependent seizures and cognition in adulthood. Dev Med Child Neurol. 2003; 45(11):782-5. DOI: 10.1017/s0012162203001440. View

Baxter P, Griffiths P, Kelly T, Gardner-Medwin D . Pyridoxine-dependent seizures: demographic, clinical, MRI and psychometric features, and effect of dose on intelligence quotient. Dev Med Child Neurol. 1996; 38(11):998-1006. DOI: 10.1111/j.1469-8749.1996.tb15060.x. View

Wolf B, Heard G, Jefferson L, Proud V, Nance W, Weissbecker K . Clinical findings in four children with biotinidase deficiency detected through a statewide neonatal screening program. N Engl J Med. 1985; 313(1):16-9. DOI: 10.1056/NEJM198507043130104. View

Cortes-Saladelafont E, Molero-Luis M, Hsjd Working Group , Artuch R, Garcia-Cazorla A . Pyridoxal Phosphate Supplementation in Neuropediatric Disorders. Semin Pediatr Neurol. 2017; 23(4):351-358. DOI: 10.1016/j.spen.2016.11.009. View

Gallagher R, Van Hove J, Scharer G, Hyland K, Plecko B, Waters P . Folinic acid-responsive seizures are identical to pyridoxine-dependent epilepsy. Ann Neurol. 2009; 65(5):550-6. DOI: 10.1002/ana.21568. View

Bok L, Halbertsma F, Houterman S, Wevers R, Vreeswijk C, Jakobs C . Long-term outcome in pyridoxine-dependent epilepsy. Dev Med Child Neurol. 2012; 54(9):849-54. DOI: 10.1111/j.1469-8749.2012.04347.x. View

Kuo M, Wang H . Pyridoxal phosphate-responsive epilepsy with resistance to pyridoxine. Pediatr Neurol. 2002; 26(2):146-7. DOI: 10.1016/s0887-8994(01)00357-5. View

Ramaekers V, Blau N . Cerebral folate deficiency. Dev Med Child Neurol. 2004; 46(12):843-51. DOI: 10.1017/s0012162204001471. View

Cowan T, Blitzer M, Wolf B . Technical standards and guidelines for the diagnosis of biotinidase deficiency. Genet Med. 2010; 12(7):464-70. DOI: 10.1097/GIM.0b013e3181e4cc0f. View

10.

Agadi S, Quach M, Haneef Z . Vitamin-responsive epileptic encephalopathies in children. Epilepsy Res Treat. 2013; 2013:510529. PMC: 3745849. DOI: 10.1155/2013/510529. View

11.

Schulpis K, Karikas G, Tjamouranis J, Regoutas S, Tsakiris S . Low serum biotinidase activity in children with valproic acid monotherapy. Epilepsia. 2001; 42(10):1359-62. DOI: 10.1046/j.1528-1157.2001.47000.x. View

12.

Torres O, Miller V, Buist N, Hyland K . Folinic acid-responsive neonatal seizures. J Child Neurol. 1999; 14(8):529-32. DOI: 10.1177/088307389901400809. View

13.

Lin J, Lin K, Masruha M, Vilanova L . Pyridoxine-dependent epilepsy initially responsive to phenobarbital. Arq Neuropsiquiatr. 2007; 65(4A):1026-9. DOI: 10.1590/s0004-282x2007000600023. View

14.

Grunewald S, Champion M, Leonard J, Schaper J, Morris A . Biotinidase deficiency: a treatable leukoencephalopathy. Neuropediatrics. 2004; 35(4):211-6. DOI: 10.1055/s-2004-821080. View

15.

Lam M . Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs. Pharmacotherapy. 2011; 31(2):164-92. DOI: 10.1592/phco.31.2.164. View

16.

Gospe Jr S . Pyridoxine-dependent seizures: new genetic and biochemical clues to help with diagnosis and treatment. Curr Opin Neurol. 2006; 19(2):148-53. DOI: 10.1097/01.wco.0000218230.81301.12. View

17.

Hyland K, Buist N, Powell B, Hoffman G, Rating D, McGrath J . Folinic acid responsive seizures: a new syndrome?. J Inherit Metab Dis. 1995; 18(2):177-81. DOI: 10.1007/BF00711760. View

18.

Glass H . Neonatal seizures: advances in mechanisms and management. Clin Perinatol. 2014; 41(1):177-90. PMC: 3925308. DOI: 10.1016/j.clp.2013.10.004. View

19.

Cirillo M, Venkatesan C, Millichap J, Stack C, Nordli Jr D . Case Report: Intravenous and Oral Pyridoxine Trial for Diagnosis of Pyridoxine-Dependent Epilepsy. Pediatrics. 2015; 136(1):e257-61. DOI: 10.1542/peds.2014-2423. View

20.

Clayton P, Surtees R, DeVile C, Hyland K, Heales S . Neonatal epileptic encephalopathy. Lancet. 2003; 361(9369):1614. DOI: 10.1016/s0140-6736(03)13312-0. View